Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Spinal Cord Injury
  4. Amikacin Dosing and Monitoring in Spinal Cord Injury Patients: Variation in Clinical Practice Between Spinal Injury Units and Differences in Experts’ Recommendations

Amikacin Dosing and Monitoring in Spinal Cord Injury Patients: Variation in Clinical Practice Between Spinal Injury Units and Differences in Experts’ Recommendations

TheScientificWorldJOURNAL, 2006 · DOI: 10.1100/tsw.2006.44 · Published: February 17, 2006

Spinal Cord InjuryPharmacologyImmunology

Simple Explanation

This study looks at how amikacin, an antibiotic, is used in spinal cord injury patients. It found that there's a lot of variation in how different hospitals and experts dose and monitor this drug. Some hospitals use it once a day, others multiple times. Some monitor drug levels in the blood, others don't. Experts also disagree on the best way to use amikacin in these patients. Because of these differences, the study suggests that there is a need for better guidelines on how to use amikacin in spinal cord injury patients to make sure it is both safe and effective.

Study Duration
Not specified
Participants
Spinal cord physicians and clinical pharmacologists
Evidence Level
Not specified

Key Findings

  • 1
    Clinical practice varies considerably across spinal units regarding amikacin administration, with some using once-daily dosing and others using divided doses.
  • 2
    Experts hold differing opinions on the ideal dosing and monitoring of amikacin therapy in spinal cord injury patients.
  • 3
    Some spinal units do not monitor serum amikacin concentrations unless the patient has renal impairment, while others adjust the dose/interval based on pharmacokinetic parameters.

Research Summary

The objective of this article was to determine the current practice on amikacin dosing and monitoring in spinal cord injury patients from spinal cord physicians and experts. This study shows that there is considerable variation in clinical practice across spinal units and even experts differ on ideal dosing and monitoring of amikacin therapy in spinal cord injury patients. As there is considerable variation in clinical practice across spinal units and experts differ on ideal dosing and monitoring of amikacin therapy in spinal cord injury patients, there is an urgent need to develop best-practice guidelines.

Practical Implications

Development of Best-Practice Guidelines

Due to the significant variation in amikacin dosing and monitoring, standardized guidelines are needed for spinal cord injury patients.

Prospective Data Collection

There is a need to collect prospective information on amikacin's clinical and microbiological efficacy, as well as ototoxicity and nephrotoxicity.

International Electronic Database

Creation of a database to record amikacin therapy details, including dosing, serum concentrations, pharmacokinetic parameters, efficacy, and adverse events, is suggested.

Study Limitations

  • 1
    The study acknowledges that it may not be possible to conduct a prospective study at a single spinal injuries center.
  • 2
    The study relies on current practices and recommendations, rather than a controlled clinical trial.
  • 3
    The generalizability of expert opinions may be limited by individual experiences and practices.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury